Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
Approved for the treatment of non-tuberculous mycobacterial pulmonary diseases caused by Mycobacterium Avium Complex (MAC) that is refractory to current treatment options (adults and post pubescent children) in line with NHSE Specialised Commissioning Policy
For long term therapy in non-cystic fibrosis bronchiectasis usually in patients having > 3 exacerbations per annum with an organism identified as being sensitive to gentamicin.
Nebulised therapy for patients on assisted ventilation, patients with tracheostomies and those with persistant bacterial bronchitis